Brii Biosciences Limited (2137.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Brii Biosciences Limited
Sector
Healthcare
Industry
Biotechnology
Employees
98
First IPO Date
July 13, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Zhi Hong | Co-founder, Executive Chairman of the Board & Chief Executive Officer | 11.67M | 1963 |
| Ankang Li | COO, Joint Secretary & Executive Director | 6.36M | 1979 |
| Sarah Qiu | Associate Director of Investor Relations | 0 | N/A |
| David Margolis | Chief Medical Officer | 0 | 1975 |
| Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources | 0 | 1976 |
| Wing Tsz FCIS | Joint Company Secretary | 0 | 1970 |
| Qing Zhu | Head of Pre-clinical Sciences and Translational Research | 0 | 1968 |
| Susannah Cantrell | Chief Business Officer | 0 | 1969 |
| Haifeng Cao | Head of China Development | 0 | 1973 |
| Eleanor de Groot | Chief Technology Officer | 0 | 1969 |
| Brian Alvin Johns | Chief Scientific Officer | 0 | 1971 |
Description
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
